DALLAS, April 13, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2015" to its store. The report provides an overview of the Pituitary ACTH Hypersecretion (Cushing's Disease)'s therapeutic pipeline.
The report "Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects.
Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Cushing disease is caused by a tumor or excess growth of the pituitary gland. Cushing's disease is rare, affecting 10 to 15 people per million each year, most commonly adults between 20 and 50 years of age. Women account for more than 70 percent of cases. The signs and symptoms of Cushing syndrome vary. Common signs and symptoms involve progressive obesity and skin changes. Other signs and symptoms include Fatigue, Muscle weakness, Depression, anxiety and irritability, Loss of emotional control, Cognitive difficulties, New or worsened high blood pressure, Glucose intolerance that may lead to diabetes, Headache, Bone loss, leading to fractures over time.
Companies discussed in this report include Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB, ElexoPharm GmbH, Ipsen S.A., Isis Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Pfizer Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314347 . (This is a premium report priced at US$2000 for a single user License.)
Drugs profile discussed in this report include ALD-1613, AT-814, ATR-101, DG-3173, ISIS-GCCRRx, ketoconazole, LCI-699, mifepristone, MPP-482, pasireotide LAR, Peptides to Antagonize ACTH Receptor for Cushing's Syndrome, Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease, Small Molecule to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism, Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease, Small Molecules to Inhibit Cortisol for Metabolic Disorders, Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders.
Featured News & Press Releases cover by this report include: Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo; Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014; Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014; Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014; Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting; Jun 19, 2014: New Research on Corcept's Korlym for Patients with Cushing's Syndrome to be Presented at ICE/ENDO 2014; Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome; Apr 10, 2012: Corcept Therapeutics Launches Korlym For Patients With Endogenous Cushing's Syndrome; Apr 09, 2012: Corcept Announces Publication Of Phase III Trial Results Of Korlym In Journal of Clinical Endocrinology and Metabolism; Mar 6, 2012: Corcept Selects PharmaForm As Primary Commercial Manufacturer For Korlym.
The report covers all the latest news and recent developments in the medication and therapeutic market. It has a list of projects that are dormant and reasons for the same. A person referring to this report will be able to analyse the market condition and understand the way forward. It helps one to build their strategies and counter-strategies to attain the competitive advantage in the market. It helps the reader to identify its competitor and gives a snapshot of the unexplored opportunities in the market. For newcomers and emerging players this information would be highly useful in order to plan its way ahead. The report assists its readers to create a proposal for in-licensing and out-licensing strategies, companies looking forward for merger and acquisition will also find this report very useful. To summarize we can say that report provides a detailed assessment of all pipeline projects ie for monotherapy as well as combination therapy. It provides a snapshot of the global therapeutic landscape of Heart Attack.
Global Markets Direct's report on Heart Attack has been compiled from personal databases of the Global Markets Direct, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Many other medical papers have been screened and the data extracted therein has been collated together as the report.
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research